Christian Leborgne

1 Bis Rue De L'Internationale
Evry, 91000, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Imlifidase enables AAV gene therapy in a seropositive Crigler-Najjar patient: On the verge of a paradigm shift.

Imlifidase enables AAV gene therapy in a seropositive Crigler-Najjar patient: On the verge of a paradigm shift.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: April 02, 2026

Semirational bioengineering of AAV vectors with increased potency and specificity for systemic gene therapy of muscle disorders.

Semirational bioengineering of AAV vectors with increased potency and specificity for systemic gene therapy of muscle disorders.

Journal: Science advances

Published: September 21, 2022

Overcoming the Challenges Imposed by Humoral Immunity to AAV Vectors to Achieve Safe and Efficient Gene Transfer in Seropositive Patients.

Overcoming the Challenges Imposed by Humoral Immunity to AAV Vectors to Achieve Safe and Efficient Gene Transfer in Seropositive Patients.

Journal: Frontiers in immunology

Published: January 18, 2022

A novel therapeutic strategy for skeletal disorders: Proof of concept of gene therapy for X-linked hypophosphatemia.

A novel therapeutic strategy for skeletal disorders: Proof of concept of gene therapy for X-linked hypophosphatemia.

Journal: Science advances

Published: October 27, 2021

IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies.

IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies.

Journal: Nature medicine

Published: January 23, 2020

Capsid-specific removal of circulating antibodies to adeno-associated virus vectors.

Capsid-specific removal of circulating antibodies to adeno-associated virus vectors.

Journal: Scientific reports

Published: October 07, 2019

Peptides derived from the C-terminal domain of HIV-1 Viral Protein R in lipid bilayers: Structure, membrane positioning and gene delivery.

Peptides derived from the C-terminal domain of HIV-1 Viral Protein R in lipid bilayers: Structure, membrane positioning and gene delivery.

Journal: Biochimica et biophysica acta. Biomembranes

Published: September 10, 2019

Erratum: Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction.

Erratum: Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction.

Journal: Molecular therapy. Methods & clinical development

Published: May 11, 2019

AAV Gene Transfer with Tandem Promoter Design Prevents Anti-transgene Immunity and Provides Persistent Efficacy in Neonate Pompe Mice.

AAV Gene Transfer with Tandem Promoter Design Prevents Anti-transgene Immunity and Provides Persistent Efficacy in Neonate Pompe Mice.

Journal: Molecular therapy. Methods & clinical development

Published: September 11, 2018

Induction of tumor-specific CTL responses using the C-terminal fragment of Viral protein R as cell penetrating peptide.

Induction of tumor-specific CTL responses using the C-terminal fragment of Viral protein R as cell penetrating peptide.

Journal: Scientific reports

Published: June 20, 2018

Exposure to wild-type AAV drives distinct capsid immunity profiles in humans.

Exposure to wild-type AAV drives distinct capsid immunity profiles in humans.

Journal: The Journal of clinical investigation

Published: May 21, 2018

Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration.

Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration.

Journal: Nature communications

Published: March 10, 2018

Showing 1-12 of 27

Last Updated: 09/26/2026